Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
'Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025' Report Highlights:
Targeted therapy has the leading share in the Japan cancer drug market while the immunotherapy is the second leading type of therapy. This is due to the ability of targeted therapies to kill only malignant cells thereby exhibiting better treatment outcomes. In addition, elevated efficacy and higher survival rates associated with the use of targeted therapy drugs are other reasons that fuel the growth of the market. In the case of immunotherapy, it is the fastest growing segment in Japan pharmaceutical market as it is widely accepted as an ideal treatment option as these drugs are potentially harmless to the other living cells of the body, which makes them less toxic as compared to other modes of cancer therapies. Hormonal therapy and chemotherapy are not commonly used in Japan as chemotherapy has several adverse effects and hormonal therapy is not able to treat all type of cancers.
In Japan, prostate and lung cancer therapeutics will lead the cancer drug market in upcoming years, which is mainly due to presence of huge geriatric population of Japan. Currently, about 28% of the total population of Japan belongs to the age more than 65 years and this share is expected to increase in upcoming years. Further, the breast cancer drug market will also emerge as the leading segment of Japan caner drug market in near future as the cases of breast cancer is increasing rapidly in Japan. The overall Cancer cases in Japan are also rising and hence the demand of anticancer drugs is expected to increase rapidly in future years.
Japanese government will also play a prominent role in the rapid growth of cancer drug market by providing favorable policies framework for easy drug approval, production and marketing of products. A policy framework change is required in order to make drug approval process simpler so that the globally available products of leading MNCs can enter the Japanese market and are easily accessible to desired targeted population. In addition to this, it is also necessary to make the drug approval process faster so that the essential and highly effective drugs get approve on right time. As the leading regional companies of Japan is witnessing sales breakdown, the government of Japan can play a major role to encourage these companies for continuous production of the branded as well as generic anticancer drugs.
Several new drugs targeting different type of cancer are about to get approved by PMDA very soon, which will take this market segment to the next level. About 1617 cancer related clinical trials related to more than 350 cancer drugs are under investigation in Japan in which about 30% trials are in late development stage. The investments related to research and development is also increasing and many innovative cancer targeting therapies is expected to get approved in Japan, which will act as game changer in the treatment of cancer.
The future of Japanese cancer drug market seems to the sustain the past growth trends and will continue to its upward growth trajectory in coming years. Cancer drug market opportunity is expected to surpass US$ 15 Billion by 2025 driven by increasing number of clinical trials, availability of multiple products and the favorable steps undertaken by various stake holders of the pharmaceutical market. The Japan cancer drug market growth will take place at tremendous pace and this segment will emerge as an ocean of opportunities in near future.
'Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025' Report Highlights:
- Japan Cancer Drug Market Opportunity: > US$ 15 Billion by 2025
- Insight on Cancer Drugs In Clinical Trials: 360 Drugs
- Ongoing Clinical Trials for Cancer Drugs: 1600 Trials
- Marketed Cancer Drug Clinical Insight by Companies & Indication: 141 Drugs
- Cancer Drug Price, Dosage & Sales Insight: 250 Graphs
- Cancer Clinical Pipeline By Company, Indication & Phase
Targeted therapy has the leading share in the Japan cancer drug market while the immunotherapy is the second leading type of therapy. This is due to the ability of targeted therapies to kill only malignant cells thereby exhibiting better treatment outcomes. In addition, elevated efficacy and higher survival rates associated with the use of targeted therapy drugs are other reasons that fuel the growth of the market. In the case of immunotherapy, it is the fastest growing segment in Japan pharmaceutical market as it is widely accepted as an ideal treatment option as these drugs are potentially harmless to the other living cells of the body, which makes them less toxic as compared to other modes of cancer therapies. Hormonal therapy and chemotherapy are not commonly used in Japan as chemotherapy has several adverse effects and hormonal therapy is not able to treat all type of cancers.
In Japan, prostate and lung cancer therapeutics will lead the cancer drug market in upcoming years, which is mainly due to presence of huge geriatric population of Japan. Currently, about 28% of the total population of Japan belongs to the age more than 65 years and this share is expected to increase in upcoming years. Further, the breast cancer drug market will also emerge as the leading segment of Japan caner drug market in near future as the cases of breast cancer is increasing rapidly in Japan. The overall Cancer cases in Japan are also rising and hence the demand of anticancer drugs is expected to increase rapidly in future years.
Japanese government will also play a prominent role in the rapid growth of cancer drug market by providing favorable policies framework for easy drug approval, production and marketing of products. A policy framework change is required in order to make drug approval process simpler so that the globally available products of leading MNCs can enter the Japanese market and are easily accessible to desired targeted population. In addition to this, it is also necessary to make the drug approval process faster so that the essential and highly effective drugs get approve on right time. As the leading regional companies of Japan is witnessing sales breakdown, the government of Japan can play a major role to encourage these companies for continuous production of the branded as well as generic anticancer drugs.
Several new drugs targeting different type of cancer are about to get approved by PMDA very soon, which will take this market segment to the next level. About 1617 cancer related clinical trials related to more than 350 cancer drugs are under investigation in Japan in which about 30% trials are in late development stage. The investments related to research and development is also increasing and many innovative cancer targeting therapies is expected to get approved in Japan, which will act as game changer in the treatment of cancer.
The future of Japanese cancer drug market seems to the sustain the past growth trends and will continue to its upward growth trajectory in coming years. Cancer drug market opportunity is expected to surpass US$ 15 Billion by 2025 driven by increasing number of clinical trials, availability of multiple products and the favorable steps undertaken by various stake holders of the pharmaceutical market. The Japan cancer drug market growth will take place at tremendous pace and this segment will emerge as an ocean of opportunities in near future.
1. JAPAN CANCER DRUG MARKET INSIGHT
1.1 Overview
1.2 Current Market Scenario
2. JAPAN - CANCER PREVALENCE & STATISTICS
2.1 Overview
2.2 By Cancer Type
2.2.1 Colorectum Cancer
2.2.2 Lung Cancer
2.2.3 Stomach Cancer
2.2.4 Prostate Cancer
2.2.5 Breast Cancer
2.3 By Gender & Age
3. JAPAN - DRUG APPROVAL & REGULATION LANDSCAPE
3.1 Japan - Drug Regulatory Agencies
3.1.1 Ministry of Health, Labor & Welfare (MHLW)
3.1.2 Pharmaceuticals and Medical Devices Agency (PMDA)
3.2 Drug Approval Process
3.2.1 New Drug Approval (NDA) Application Process
3.2.2 Generic Drug approval Process
3.2.3 Orphan Drug Approval
4. JAPAN - DRUG PRICING & REIMBURSEMENT POLICIES
4.1 Drug Pricing in Japan
4.1.1 Pricing of New Pharmaceuticals
4.1.2 Pricing of Generics & Biosimilars
4.2 Reimbursement Policies
5. JAPAN CANCER DRUG MARKET - CLINICAL INSIGHT
5.1 By Phase
5.2 By Status
5.3 By Cancer Type
5.3.1 Breast Cancer
5.3.2 Colorectal Cancer
5.3.3 Prostate Cancer
5.3.4 Lung Cancer
5.3.5 Stomach Cancer
6. JAPAN BREAST CANCER DRUG MARKET - AVAILABILITY, DOSAGE & PRICE ANALYSIS
6.1 HER2 inhibitors
6.1.1 Herceptin
6.1.2 Kadcyla
6.1.3 Perjeta (Pertuzumab)
6.1.4 Enhertu (Antibody Drug Conjugate)
6.1.5 Tykerb (Lapatinib)
6.2 Hormone Therapy
6.2.1 Letrozole
6.2.2 Anastrazole (Arimidex)
6.2.3 Megestrol
6.2.4 Faslodax (Fulvestrant)
6.2.5 Toremifene
6.2.6 Exemestane (Aromasin)
6.3 CDK 4/6 Inhibitors
6.3.1 Verzenio (Abemaciclib)
6.3.2 Ibrance
7. JAPAN PROSTATE CANCER DRUG MARKET – AVAILABILITY, DOSAGE & PRICE ANALYSIS
7.1 Patented Drugs
7.1.1 Xtandi (Enzalutamide)
7.1.2 Erleada (Apalutamide)
7.1.3 Nubeqa
7.1.4 Xofigo (Radium Ra 223 dichloride)
7.2 Generic Drugs
7.2.1 Abiraterone
7.2.2 Bicalutamide
7.2.3 Nilutamide
7.2.4 Flutamide
8. JAPAN LUNG CANCER DRUG MARKET – AVAILABILITY, DOSAGE & PRICE ANALYSIS
8.1 Patented Drugs
8.1.1 Alimta (Pemetrexed)
8.1.2 Alecensa (Alectinib)
8.1.3 Gilotrif
8.1.4 Lorbrena
8.1.5 Portrazza (Necitimumab)
8.1.6 Rozlytrek
8.1.7 Tagrisso
8.1.8 Vizimpro (Dacomitinib)
8.1.9 Xalkori (Crizotinib)
8.1.10 Zykadia (Certinib)
8.2 Generic Drugs
8.2.1 Vinorelbine
9. JAPAN COLORECTUM CANCER DRUG MARKET – AVAILABILITY, DOSAGE & PRICE ANALYSIS
9.1 Patented drugs
9.1.1 Lonsurf
9.1.2 Vectibix (Panitumumab)
9.1.3 Zaltrap
9.2 Generic Drugs
9.2.1 Irinotecan
9.2.2 Oxaliplatin
10. OTHER LEADING CANCER DRUGS – AVAILABILITY, DOSAGE, PRICE & SALES ANALYSIS
10.1 Avastin (Bevacizumab)
10.2 Mabthera/Rituxan
10.3 Tecentriq
10.4 Opdivo
10.5 Revlimid
10.6 Keytruda
10.7 Imbruvica
11. JAPAN CANCER BIOSIMILAR MARKET – AVAILABILITY, DOSAGE & PRICE ANALYSIS
11.1 Biosimilar of Avastin
11.2 Biosimilars of Herceptin
11.3 Rituxan’s Biosimilar
12. JAPAN CANCER DRUGS MARKET DYNAMICS
12.1 Market Drivers
12.2 Challenges to Overcome
13. JAPAN CANCER DRUG MARKET FUTURE OUTLOOK
14. JAPAN CANCER CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
14.1 Research
14.2 Preclinical
14.3 Clinical
14.4 Phase-I
14.5 Phase-I/II
14.6 Phase-II
14.7 Phase-II/III
14.8 Phase-III
14.9 Preregistration
14.10 Registered
15. JAPAN MARKETED CANCER DRUG CLINICAL INSIGHT BY COMPANIES & INDICATION
16. COMPETITIVE LANDSCAPE
16.1 Regional Companies
16.1.1 Takeda Pharmaceuticals
16.1.2 Daiichi Sankyo
16.1.3 Kyowa Kirin
16.1.4 Mitsubishi Taneba Pharma Co.
16.1.5 Otsuka Pharmaceutical Co. Ltd.
16.1.6 Eisai Co. Ltd.
16.1.7 Astellas Pharma
16.2 Multinational Company
16.2.1 Novartis
16.2.2 Amgen
16.2.3 Eli Lilly
16.2.4 Merck
16.2.5 Pfizer
16.2.6 GlaxoSmithKline plc
16.2.7 Roche
1.1 Overview
1.2 Current Market Scenario
2. JAPAN - CANCER PREVALENCE & STATISTICS
2.1 Overview
2.2 By Cancer Type
2.2.1 Colorectum Cancer
2.2.2 Lung Cancer
2.2.3 Stomach Cancer
2.2.4 Prostate Cancer
2.2.5 Breast Cancer
2.3 By Gender & Age
3. JAPAN - DRUG APPROVAL & REGULATION LANDSCAPE
3.1 Japan - Drug Regulatory Agencies
3.1.1 Ministry of Health, Labor & Welfare (MHLW)
3.1.2 Pharmaceuticals and Medical Devices Agency (PMDA)
3.2 Drug Approval Process
3.2.1 New Drug Approval (NDA) Application Process
3.2.2 Generic Drug approval Process
3.2.3 Orphan Drug Approval
4. JAPAN - DRUG PRICING & REIMBURSEMENT POLICIES
4.1 Drug Pricing in Japan
4.1.1 Pricing of New Pharmaceuticals
4.1.2 Pricing of Generics & Biosimilars
4.2 Reimbursement Policies
5. JAPAN CANCER DRUG MARKET - CLINICAL INSIGHT
5.1 By Phase
5.2 By Status
5.3 By Cancer Type
5.3.1 Breast Cancer
5.3.2 Colorectal Cancer
5.3.3 Prostate Cancer
5.3.4 Lung Cancer
5.3.5 Stomach Cancer
6. JAPAN BREAST CANCER DRUG MARKET - AVAILABILITY, DOSAGE & PRICE ANALYSIS
6.1 HER2 inhibitors
6.1.1 Herceptin
6.1.2 Kadcyla
6.1.3 Perjeta (Pertuzumab)
6.1.4 Enhertu (Antibody Drug Conjugate)
6.1.5 Tykerb (Lapatinib)
6.2 Hormone Therapy
6.2.1 Letrozole
6.2.2 Anastrazole (Arimidex)
6.2.3 Megestrol
6.2.4 Faslodax (Fulvestrant)
6.2.5 Toremifene
6.2.6 Exemestane (Aromasin)
6.3 CDK 4/6 Inhibitors
6.3.1 Verzenio (Abemaciclib)
6.3.2 Ibrance
7. JAPAN PROSTATE CANCER DRUG MARKET – AVAILABILITY, DOSAGE & PRICE ANALYSIS
7.1 Patented Drugs
7.1.1 Xtandi (Enzalutamide)
7.1.2 Erleada (Apalutamide)
7.1.3 Nubeqa
7.1.4 Xofigo (Radium Ra 223 dichloride)
7.2 Generic Drugs
7.2.1 Abiraterone
7.2.2 Bicalutamide
7.2.3 Nilutamide
7.2.4 Flutamide
8. JAPAN LUNG CANCER DRUG MARKET – AVAILABILITY, DOSAGE & PRICE ANALYSIS
8.1 Patented Drugs
8.1.1 Alimta (Pemetrexed)
8.1.2 Alecensa (Alectinib)
8.1.3 Gilotrif
8.1.4 Lorbrena
8.1.5 Portrazza (Necitimumab)
8.1.6 Rozlytrek
8.1.7 Tagrisso
8.1.8 Vizimpro (Dacomitinib)
8.1.9 Xalkori (Crizotinib)
8.1.10 Zykadia (Certinib)
8.2 Generic Drugs
8.2.1 Vinorelbine
9. JAPAN COLORECTUM CANCER DRUG MARKET – AVAILABILITY, DOSAGE & PRICE ANALYSIS
9.1 Patented drugs
9.1.1 Lonsurf
9.1.2 Vectibix (Panitumumab)
9.1.3 Zaltrap
9.2 Generic Drugs
9.2.1 Irinotecan
9.2.2 Oxaliplatin
10. OTHER LEADING CANCER DRUGS – AVAILABILITY, DOSAGE, PRICE & SALES ANALYSIS
10.1 Avastin (Bevacizumab)
10.2 Mabthera/Rituxan
10.3 Tecentriq
10.4 Opdivo
10.5 Revlimid
10.6 Keytruda
10.7 Imbruvica
11. JAPAN CANCER BIOSIMILAR MARKET – AVAILABILITY, DOSAGE & PRICE ANALYSIS
11.1 Biosimilar of Avastin
11.2 Biosimilars of Herceptin
11.3 Rituxan’s Biosimilar
12. JAPAN CANCER DRUGS MARKET DYNAMICS
12.1 Market Drivers
12.2 Challenges to Overcome
13. JAPAN CANCER DRUG MARKET FUTURE OUTLOOK
14. JAPAN CANCER CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
14.1 Research
14.2 Preclinical
14.3 Clinical
14.4 Phase-I
14.5 Phase-I/II
14.6 Phase-II
14.7 Phase-II/III
14.8 Phase-III
14.9 Preregistration
14.10 Registered
15. JAPAN MARKETED CANCER DRUG CLINICAL INSIGHT BY COMPANIES & INDICATION
16. COMPETITIVE LANDSCAPE
16.1 Regional Companies
16.1.1 Takeda Pharmaceuticals
16.1.2 Daiichi Sankyo
16.1.3 Kyowa Kirin
16.1.4 Mitsubishi Taneba Pharma Co.
16.1.5 Otsuka Pharmaceutical Co. Ltd.
16.1.6 Eisai Co. Ltd.
16.1.7 Astellas Pharma
16.2 Multinational Company
16.2.1 Novartis
16.2.2 Amgen
16.2.3 Eli Lilly
16.2.4 Merck
16.2.5 Pfizer
16.2.6 GlaxoSmithKline plc
16.2.7 Roche
LIST OF FIGURES
Figure 1-1: Japan – Per Capita Healthcare Expenditure (US$/JPY), 2017 & 2018
Figure 1-2: Japan – Heath care Expenditure (US$/JPY Billion), 2017 & 2018
Figure 1-3: Japan – Per Capita Heath care Expenditure by Age (US$/JPY), 2018
Figure 1-4: Global - Pharmaceutical Market Size by Leading Countries (US$ Billion), 2018
Figure 1-5: Global - Pharmaceutical Market Size by Leading Countries (US$ Billion), 2018
Figure 1-6: Estimated Cancer Cases – Global v/s Japan (Million), 2020
Figure 1-7: Japan – Cancer Drug Market Size (US$ Billion), 2018 - 2025
Figure 1-8: Cancer Drug Market Size – Japan v/s Global (US$ Billion), 2019
Figure 1-9: Cancer Drug Market Size – Japan v/s Global (US$ Billion), 2019
Figure 1-10: Japan – Volume Share of Generics (%), 2011 , 2015, 2017 & 2020
Figure 2-1: Japan – Newly Diagnosed Cancer Cases, 2018, 2020 & 2025
Figure 2-2: Japan – Cancer Deaths Statistics, 2018, 2020 & 2025
Figure 2-3: Age Standardized Cancer Incidence Rate – Japan v/s Global Average (Per 100,000), 2018
Figure 2-4: Age Standardized Cancer Mortality Rate – Japan v/s Global Average (Per 100,000), 2018
Figure 2-5: Japan – Newly Diagnosed Cancer Cases by Type, 2018
Figure 2-6: Japan – Newly Diagnosed Cancer Cases by Type (%), 2018
Figure 2-7: Japan – Cancer Related Deaths by Type, 2018
Figure 2-8: Japan – Newly Diagnosed Colorectum Cancer Cases, 2018, 2020 & 2025
Figure 2-9: Japan – Newly Diagnosed Colorectum Cancer Cases by Type, 2018
Figure 2-10: Japan –Colorectum Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-11: Japan – Age Standardized Colorectum Cancer Incidence & Mortality Rate (Per 100,000), 2018
Figure 2-12: Japan – Newly Diagnosed Lung Cancer Cases, 2018, 2020 & 2025
Figure 2-13: Japan –Lung Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-14: Japan – Age Standardized Lung Cancer Incidence & Mortality Rate (Per 100,000), 2018
Figure 2-15: Japan – Newly Diagnosed Stomach Cancer Cases, 2018, 2020 & 2025
Figure 2-16: Japan – Stomach Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-17: Japan – Age Standardized Stomach Cancer Incidence & Mortality Rate (Per 100,000), 2018
Figure 2-18: Japan – Newly Diagnosed Prostate Cancer Cases, 2018, 2020 & 2025
Figure 2-19: Japan – Prostate Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-20: Japan – Age Standardized Prostate Cancer Incidence & Mortality Rate (Per 100,000), 2018
Figure 2-21: Japan – Newly Diagnosed Breast Cancer Cases, 2018, 2020 & 2025
Figure 2-22: Japan – Breast Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-23: Japan – Age Standardized Breast Cancer Incidence & Mortality Rate (Per 100,000), 2018
Figure 2-24: Japan – Newly Diagnosed Cancer Cases by Gender, 2018
Figure 2-25: Japan – Cancer Deaths by Gender, 2018
Figure 2-26: Japan – Age Standardized Cancer Incidence Rate by Gender (Per 100,000), 2018
Figure 2-27: Japan – Age Standardized Cancer Mortality Rate by Gender (Per 100,000), 2018
Figure 2-28: Japan – Estimated Number of Newly Diagnosed Cancer Cases in Males, 2020 & 2025
Figure 2-29: Japan – Estimated Number of Newly Diagnosed Cancer Cases in Females, 2020 & 2025
Figure 2-30: Japan – Male Cancer Cases by Type, 2018
Figure 2-31: Japan – Male Cancer Cases by Type, 2018
Figure 2-32: Japan – Male Cancer Cases by Type, 2018
Figure 2-33: Japan – Female Cancer Cases by Type, 2018
Figure 2-34: Japan – Female Cancer Cases by Type (%), 2018
Figure 2-35: Japan – Female Cancer Cases by Type, 2018
Figure 2-36: Japan – Newly Diagnosed Cancer Cases by Age, 2018
Figure 2-37: Japan – Newly Diagnosed Cancer Cases by Age (%), 2018
Figure 2-38: Japan – Newly Diagnosed Cancer Cases by Age, 2018
Figure 2-39: Japan – Newly Diagnosed Cancer Cases by Age (%), 2018
Figure 3-1: Japan – PMDA Review Process for Drugs & Medical Devices
Figure 3-2: Japan - PMDA Regulatory System for Practical Application of Cellular & Tissue Based Product
Figure 3-3: Japan - Organisation of PMDA
Figure 3-4: Japan – New Drug Marketing Approval Process
Figure 4-1: Outline of Pricing New Pharmaceuticals
Figure 4-2: Japan - Premium Applied During Price Fixation of New Pharmaceuticals
Figure 4-3: Japan - Components of Cost Calculation Method
Figure 4-4: Japan - Price of New Generic & Oral Generic with more than 10 Brands v/s Original Product (%), April’2020
Figure 4-5: Japan – Price of Biotechnological & Chemically derived Biosimilars v/s Original Products
Figure 4-6: Japan: Price Reduction of Branded Drugs by Generic Replacement Rate (%)
Figure 5-1: Japan – Number of Clinical Trial related to Cancer v/s Total, April’2020
Figure 5-2: Japan – Number of Clinical Trial related to Cancer v/s Total (%), April’2020
Figure 5-3: Japan – Number of Clinical Trial by Phase, April’2020
Figure 5-4: Japan – Number of Clinical Trials by Phase (%), April’2020
Figure 5-5: Japan – Number of Drug In Clinical Trials by Phase, 2020 till 2025
Figure 5-6: Japan – Number of Drug In Clinical Trials by Phase, 2020 till 2025
Figure 5-7: Japan – Number of Clinical Trial by Status, April’2020
Figure 5-8: Japan – Number of Breast Cancer Clinical Trial by Phase, April’2020
Figure 5-9: Japan – Number of Breast Cancer Clinical Trial by Phase (%), April’2020
Figure 5-10: Japan – Number of Breast Cancer Clinical Trial by Status, April’2020
Figure 5-11: Japan – Number of Colorectum Cancer Clinical Trial by Phase, April’2020
Figure 5-12: Japan – Number of Colorectum Cancer Clinical Trial by Phase (%), April’2020
Figure 5-13: Japan – Number of Colorectum Cancer Clinical Trial by Status, April’2020
Figure 5-14: Japan – Number of Prostate Cancer Clinical Trial by Phase, April’2020
Figure 5-15: Japan – Number of Colorectum Cancer Clinical Trial by Phase (%), April’2020
Figure 5-16: Japan – Number of Prostate Cancer Clinical Trial by Status, April’2020
Figure 5-17: Japan – Number of Lung Cancer Clinical Trial by Phase, April’2020
Figure 5-18: Japan – Number of Lung Cancer Clinical Trial by Phase (%), April’2020
Figure 5-19: Japan – Number of Lung Cancer Clinical Trial by Status, April’2020
Figure 5-20: Japan – Number of Stomach Cancer Clinical Trial by Phase, April’2020
Figure 5-21: Japan – Number of Lung Cancer Clinical Trial by Phase (%), April’2020
Figure 5-22: Japan – Number of Lung Cancer Clinical Trial by Status, April’2020
Figure 6-1: Breast Cancer Drug Market Size – Global v/s Japan (US$ Billion), 2019
Figure 6-2: Breast Cancer Drug Market Size – Global v/s Japan (%), 2019
Figure 6-3: Herceptin – Approval Year by Cancer Type
Figure 6-4: Herceptin – FDA approval & PMDA Approval Year
Figure 6-5: Herceptin – Price for a Supply of 10 and Price for Single 150mg Powder for Injection (US$/JPY), June’2020
Figure 6-6: Herceptin – Initial & Maintenance Dose for Breast Cancer Treatment (mg/kg), June’2020
Figure 6-7: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Breast Cancer (US$/JPY), June’2020
Figure 6-8: Herceptin – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), January’2020
Figure 6-9: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$/JPY), January’2020
Figure 6-10: Japan – Herceptin Annual Sales Value (US$/JPY Million), 2017 - 2019
Figure 6-11: Japan – Herceptin Quarterly Sales Value (US$/JPY Million), 2019
Figure 6-12: Japan – Herceptin Quarterly Sales Value (US$/JPY Million), 2019
Figure 6-13: Kadcyla – FDA Approval Year for Late Stage & Early Stage HER2+ Breast Cancer
Figure 6-14; Kadcyla – Price for Single Unit of 100mg & 150mg Intravenous Powder for Injection (US$), June’2020
Figure 6-15: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks), June’2020
Figure 6-16: Kadcyla – Average Cost of Single Treatment Cycle & Full Treatment of Early Stage HER2 Breast Cancer (US$/JPY), June’2020
Figure 6-17: Kadcyla – Recommended Dose After 1st & 2nd Dose Reduction (mg/m2), June’2020
Figure 6-18: Perjeta – FDA & PMDA Approval Year
Figure 6-19: Perjeta – Patent Expiration Year by Region
Figure 6-20: Perjeta – Price for a Supply of 10 ml and Price per ml of Intravenous Solution (US$/JPY), June’2020
Figure 6-21: Perjeta – Initial & Maintenance Dose for Breast Cancer Treatment (mg/ 3 weeks), June’2020
Figure 6-22: Perjeta – Minimum & Maximum Treatment Cost for Breast Cancer (US$/JPY), June’2020
Figure 6-23: Perjeta – Minimum & Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$/JPY), January’2020
Figure 6-24: Japan – Perjeta Annual Sales Value (US$/JPY Million), 2017 - 2019
Figure 6-25: Japan – Perjeta Quarterly Sales Value (US$/JPY Million), 2019
Figure 6-26: Japan – Perjeta Quarterly Sales Value (US$/JPY Million), 2019
Figure 6-27: Enhertu – FDA & PMDA Approval Year
Figure 6-28: Enhertu – Disease Control, Tumor Shrinkage & Disease Elimination Rate (%)
Figure 6-29: Enhertu – Average Cost of Single Treatment Cycle & Annual Treatment Cost of Breast Cancer (US$/JPY), June’2020
Figure 6-30: Enhertu – Recommended Dose & Dose after Reduction (mg/Kg), June’2020
Figure 6-31: Tykerb – FDA & Japan Approval Year
Figure 6-32: Tykerb – Patent Issue & Expiration Year
Figure 6-33: Tykerb – Price for 150 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 6-34: Tykerb – for HER2+ & HER2+ Metastatic Breast Cancer (mg per day), April’2020
Figure 6-35: Tykerb – Treatment & Rest Phase in Single Treatment Cycle (Days)
Figure 6-36: Letrozole – FDA & PMDA Approval Year
Figure 6-37: Letrozole – Price for a Supply of 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-38: Letrozole – Price for a Supply of 50 Tablets & Price per Unit Tablet (US$), June’2020
Figure 6-39: Letrozole – Price for a Supply of 90 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-40: Letrozole – Price for a Supply of 1000 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-41: Femara – Price for a Supply of 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-42: Letrozole – Daily, Monthly & Annual Treatment Cost using Branded & Generic Letrozole (US$), June’2020
Figure 6-43: Anastarzole - FDA & Generic Approval Year
Figure 6-44: Anastrazole - Price for Various Supplies of 1mg Tablet (US$/JPY), June’2020
Figure 6-45: Arimidex – Price for 30 Tablet Supply & Price Per Unit Tablet (US$/JPY), June’2020
Figure 6-46: Anastrazole – Daily, Monthly & Annual Treatment Cost for Breast Cancer (US$), 2020’January
Figure 6-47: Armidex – Daily, Monthly & Annual Treatment Cost for Breast Cancer (US$), 2020’January
Figure 6-48: Megastrol - FDA & Generic Approval Year
Figure 6-49: Megastrol – Price for Various Supplies of 40mg/ml Oral Suspension (US$/JPY), June’2020
Figure 6-50: Megastrol - Price for Supply of 150 ml & Price per ml of 625mg/5ml Oral Suspension (US$/JPY), June’2020
Figure 6-51: Megace ES - Price for Supply of 150 ml & Price per ml of 625mg/5ml Oral Suspension (US$/JPY), June’2020
Figure 6-52: Megastrol - Price for Supply of 100 Tablets & Price per Unit of 20mg Tablet (US$/JPY), June’2020
Figure 6-53: Megastrol - Price for Supply of 100, 250 & 500 Tablets of 40mg (US$/JPY), June’2020
Figure 6-54: Megestrol - Average Cost of Daily, Monthly & Annual Treatment using 40mg/ml Oral Suspension (US$), June’2020
Figure 6-55: Megestrol - Average Cost of Daily, Monthly & Annual Treatment using 40mg Oral Tablet (US$), June’2020
Figure 6-56: Fulvestrant - FDA & PMDA Approval Year
Figure 6-57: Fulvestrant – Average Price for a Supply of 10ml, 5ml & Price per ml of Intramuscular Solution (US$/JPY), June’2020
Figure 6-58: Faslodex – Average Price for a Supply of 10ml, 5ml & Price per ml of Intramuscular Solution (US$/JPY), June’2020
Figure 6-59: Fulvestrant – Number of Dose Administration in Initial & Subsequent Months, January’2020
Figure 6-60: Fulvestrant – Treatment Cost of Initial & Subsequent Months (US$), January’2020
Figure 6-61: Fulvestrant – Treatment Cost of Initial & Subsequent Year (US$), January’2020
Figure 6-62: Faslodex – Treatment Cost of Initial & Subsequent Months (US$), January’2020
Figure 6-63: Faslodex – Treatment Cost of Initial & Subsequent Year (US$), January’2020
Figure 6-64: Toremifene - FDA & First Generic Approval Year
Figure 6-65: Toremifene – Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-66: Fareston – Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-67: Toremifene - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020’January
Figure 6-68: Fareston - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020’January
Figure 6-69: Exemestane - FDA & First Generic Approval Year
Figure 6-70: Exemestane – Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-71: Aromasin – Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-72: Exemestane - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020’January
Figure 6-73: Aromasin - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020’January
Figure 6-74: Verzenio – FDA & PMDA Approval Year
Figure 6-75: Verzenio – Patent Issue & Expiration Year
Figure 6-76: Verzenio - Price for a Supply of 14 Tablets & Price per unit of Tablet (US$/JPY), June’2020
Figure 6-77: Verzenio - Recommanded Dose Modification for Adverse Effects in Monotherapy (mg)
Figure 6-78: Verzenio - Recommanded Dose Modification for Adverse Effects in Combinational Therapy (mg)
Figure 6-79: Ibrance – FDA & PMDA Approval Year
Figure 6-80: Ibrance - Year of Assigning & Expiration of Different Patents
Figure 6-81: Ibrance – Price for a Supply of 21 Capsules & Per Unit Cost of Ibrance Capsules (US$/JPY), June’2020
Figure 6-82: Ibrance – Treatment Cycle of Ibrance using 1 Capsule/Day (Days)
Figure 6-83: Ibrance – Recommanded Dose Modification for Adverse effects (mg)
Figure 7-1: Xtandi – FDA & Japan Approval Year
Figure 7-2: Xtandi – Patent Issue & expiration Year
Figure 7-3: Xtandi – Price for 120 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 7-4: Xtandi – Recommended & Reduced Dose for Prostate Cancer Treatment (mg per day), April’2020
Figure 7-5: Xtandi – Cost of Single Capsule & Daily Treatment Cost (JPY/US$), April’2020
Figure 7-6: Erleada – FDA & Japan Approval Year
Figure 7-7: Erleada – Aragon related Patent Issue & expiration Year
Figure 7-8: Erleada – University of California related Patent Issue & expiration Year
Figure 7-9: Erleada – Price for 120 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 7-10: Erleada – Recommended & Reduced Dose for Prostate Cancer Treatment (mg per day), April’2020
Figure 7-11: Nubeqa – FDA & Japan Approval Year
Figure 7-12: Nubeqa – Aragon related Patent Issue & Expiration Year
Figure 7-13: Nubeqa – Price for 120 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 7-14: Nubeqa – Price of Single Tablet & Daily Treatment Cost (JPY/US$), April’2020
Figure 7-15: Xofigo – FDA & Japan Approval Year
Figure 7-16: Xofigo – Patent Issue & expiration Year
Figure 7-17: Xofigo – Duration of One Treatment Cycle & Full Treatment Duration for Prostate Cancer (Weeks), April’2020
Figure 7-18: Abiraterone - FDA & PMDA Approval Year
Figure 7-19: Aberaterone – Price of 30 Tablets & Price per unit of 250mg Tablet (US$/JPY), June’2020
Figure 7-20: Aberaterone – Price of 120 Tablets & Price per Unit of 250mg Tablet (US$/JPY), June’2020
Figure 7-21: Zytiga – Price of 120 Tablets & Price per unit of 250mg Tablet (US$/JPY), June’2020
Figure 7-22: Zytiga – Price of 60 Tablets & Price per Unit of 500mg Tablet (US$/JPY), June’2020
Figure 7-23: Abiraterone – Treatment Cost Comparision of Metastatic High-risk CSPC Using Branded & Generic Tablet (US$), January’2020
Figure 7-24: Abiraterone – Treatment Cost Comparision of Metastatic CSPC Using Branded & Generic Tablet (US$), January’2020
Figure 7-25: Bicalutamide - FDA & First Generic Approval Year
Figure 7-26: Bicalutamide - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 7-27: Casodex - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 7-28: Bicalutamide – Price of 100 Tablets & Price per Unit of 50mg Tablet (US$/JPY), June’2020
Figure 7-29: Bicalutamide – Price of 500 Tablets & Price per Unit of 50mg Tablet (US$/JPY), June’2020
Figure 7-30: Bicalutamide – Treatment Cost Comparision of Prostate Cancer Using Branded & Generic Tablet (US$), January’2020
Figure 7-31: Nilutamide - FDA & First Generic Approval Year
Figure 7-32: Nilutamide - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 7-33: Nilandron - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 7-34: Nilutamide – Initial & Maintenance Dose for Prostate Cancer Treatment (mg/day)
Figure 7-35: Nilutamide – Comparision of Initial Month Treatment Cost of Prostate Cancer Using Branded & Generic Tablet (US$), June’2020
Figure 7-36: Nilutamide – Comparision of Maintenence Month Treatment Cost of Prostate Cancer Using Branded & Generic Tablet (US$), June’2020
Figure 7-37: Flutamide - FDA & First Generic Approval Year
Figure 7-38: Flutamide - Price for 180 Capsules & Price per Unit Capsule (US$/JPY), June’2020
Figure 7-39: Eulexin - Price for 180 Capsules & Price per Unit Capsule (US$/JPY), June’2020
Figure 7-40: Flutamide – Comparision of Daily, Monthly & Annual Treatment of Prostate Cancer Using Branded & Generic Capsule (US$), January’2020
Figure 8-1: Alimta – FDA & Japan Approval Year
Figure 8-2: Alimta – Patent Issue & expiration Year
Figure 8-3: Alimta – Price for 120 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 8-4: Alimta – Number of Treatment Cycle Required in Combination with Pembtrolizumab & Cisplatin , April’2020
Figure 8-5: Alecensa – FDA & Japan Approval Year
Figure 8-6: Alecensa - Patent Issue & expiration Year
Figure 8-7: Alecensa – Price for 240 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 8-8: Alecensa - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 8-9: Gilotrif – FDA & Japan Approval Year
Figure 8-10: Gilotrif - Patent Issue & expiration Year
Figure 8-11: Gilotrif – Price for 30 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 8-12: Gilotrif - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 8-13: Iressa – FDA & Japan Approval Year
Figure 8-14: Iressa – Price for 30 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 8-15: Lorbrena – FDA Approval, Japan Approval & Patent expiration Years
Figure 8-16: Lorbrena - Price for 30 Tablet Supply & Price per unit of 25mg Oral Tablet (JPY/US$), April’2020
Figure 8-17: Lorbrena - Price for 30 Tablet Supply & Price per unit of 100 mg Oral Tablet (JPY/US$), April’2020
Figure 8-18: Lorbrena - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 8-19: Portrazza - FDA & Japan Approval Year
Figure 8-20: Portrazza - Price for 50 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 8-21: Portrazza – Cost of Single Treatment Cycle & Annual Treatment Cost of NSCLC (JPY/US$), April’2020
Figure 8-22: Rozlytrek - FDA Approval, Japan Approval & Patent Expiration Year
Figure 8-23: Rozyltrek - Price for 30 Capsules Supply & Price per Unit of 100 mg Oral Tablet (JPY/US$), April’2020
Figure 8-24: Rozyltrek - Price for 90 Capsules Supply & Price per unit of 200 mg Oral Tablet (JPY/US$), April’2020
Figure 8-25: Rozyltrek – Pediatric Dose by Surface Area (mg), April’2020
Figure 8-26: Tagrisso - FDA & Japan Approval Year
Figure 8-27: Tagrisso - Patent Issue & Expiration Year
Figure 8-28: Tagrisso - Price for 30 Tablet Supply & Price per Unit of 200 mg Oral Tablet (JPY/US$), April’2020
Figure 8-29: Tagrisso - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 8-30: Vizimpro - FDA & Japan Approval Year
Figure 8-31: Vizimpro - Patent Issue & Expiration Year
Figure 8-32: Vizimpro - Price for 30 Tablet Supply & Price per Unit of 200 mg Oral Tablet (JPY/US$), April’2020
Figure 8-33: Vizimpro - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 8-34: Xalkori - FDA & Japan Approval Year
Figure 8-35: Xalkori - Patent Issue & Expiration Year
Figure 8-36: Xalkori - Price for 60 Capsule Supply & Price per Unit of Oral Capsule (JPY/US$), April’2020
Figure 8-37: Zykadia - FDA & Japan Approval Year
Figure 8-38: Zykadia - Patent Expiration Year by Assignee
Figure 8-39: Zykadia - Price for 84 Capsules Supply & Price per Unit of Oral Capsule (JPY/US$), April’2020
Figure 8-40: Zykadia - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 8-41: Vinorelbine - FDA & First Generic Approval Year
Figure 8-42: Vinorelbine - Price for 5ml Supply & Price per ml of Intravenous Solution (US$/JPY), June’2020
Figure 8-43: Vinorelbine - Price for 5ml Supply & Price per ml of Intravenous Solution (US$/JPY), June’2020
Figure 8-44: Vinorelbine Monotherapy – Comparision of Treatment Cost of NSCLC Using Branded & Generic Intravenous Solution (US$), January’2020
Figure 8-45: Vinorelbine – Combinational Dose with 100mg/m2 and 120 mg/m2 Cisplatin (mg/m2), January’2020
Figure 9-1: Lonsurf – FDA Approval, Japan Approval & Patent Expiration Year
Figure 9-2: Lonsurf - Price for Various Supplies of 6.14 mg-15 mg Tablet (JPY/US$), April’2020
Figure 9-3: Lonsurf - Price for Various Supplies of 8.19mg-20mg Tablet (JPY/US$), April’2020
Figure 9-4: Lonsurf - Recommended Dose by Surface Area (mg per day)
Figure 9-5: Vectibix – FDA & Japan Approval Year
Figure 9-6: Vectibix - Price for 5 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 9-7: Vectibix - Price for 20 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 9-8: Zaltrap - FDA & Japan Approval Year
Figure 9-9: Zaltrap - Price for 4 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 9-10: Zaltrap - Price for 8ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 9-11: Irinotecan - FDA & First Generic Approval Year
Figure 9-12: Irinotecan – Price for Various Supplies of Intravenous Solution (US$/JPY), June’2020
Figure 9-13: Camptosar – Price for Various Supplies of Intravenous Solution (US$/JPY), June’2020
Figure 9-14: Irinotecan – Minimum & Maximum Duration of Treatment Cycle (Weeks), January ’2020
Figure 9-15: Oxaliplatin - FDA & PMDA Approval Year
Figure 9-16: Oxaliplatin – Price of 50 mg & 100 mg Intravenous Powder for Injection (US$/JPY), June’2020
Figure 9-17: Oxaliplatin – Price of 10ml & 1ml Intravenous Solution for Injection (US$/JPY), June’2020
Figure 9-18: Eloxatin – Price of 10ml & 1ml Intravenous Solution for Injection (US$/JPY), June’2020
Figure 9-19: Eloxatin – Price of 20ml & 1ml Intravenous Solution for Injection (US$/JPY), June’2020
Figure 9-20: Oxaplatin – Duration of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (Weeks), 2020’January
Figure 10-1: Avastin – FDA & PMDA Approval Year
Figure 10-2: Avastin – Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US$/JPY), June’2020
Figure 10-3: Avastin – Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US$/JPY), June’2020
Figure 10-4: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$/JPY), June’2020
Figure 10-5: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$/JPY), June’2020
Figure 10-6: Avastin – Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks), June’2020
Figure 10-7: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$/JPY), June’2020
Figure 10-8: Japan – Avastin Annual Sales Value (US$/JPY Million), 2017 - 2019
Figure 10-9: Japan – Avastin Quarterly Sales Value (US$/JPY Million), 2019
Figure 10-10: Japan – Avastin Quarterly Sales Value (US$/JPY Million), 2019
Figure 10-11: Gazyva – FDA Approval Year by Indication
Figure 10-12: Rituxan - FDA & Japan Approval Year
Figure 10-13: Rituxan – Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$/JPY), June’2020
Figure 10-14: Rituxan – Price for a Supply of 50 ml & Price per ml of Solution for Injection (US$/JPY), June’2020
Figure 10-15: Rituxan – Price for a Supply of 100 ml & Price per ml of Solution for Injection (US$/JPY), June’2020
Figure 10-16: Rituxan – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$/JPY), June’2020
Figure 10-17: Rituxan – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 10-18: Japan – Rituxan Annual Sales Value (US$/JPY Million), 2017 - 2019
Figure 10-19: Japan – Rituxan Quarterly Sales Value (US$/JPY Million), 2019
Figure 10-20: Japan – Rituxan Quarterly Sales Value (US$/JPY Million), 2019
Figure 10-21: Tecentriq - FDA & Japan Approval Year
Figure 10-22: Tecentriq - Price for 14ml Supply & Price per ml of 840mg/14ml Intravenous Injection (US$/JPY), June’2020
Figure 10-23: Tecentriq - Price for 20ml Supply & Price per ml of 1200mg/20ml Intravenous Injection (US$/JPY), June’2020
Figure 10-24: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 840mg/m2 Week Dose (US$/JPY), June’2020
Figure 10-25: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1200mg/3 Week Dose (US$/JPY), June’2020
Figure 10-26: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1680mg/4 Week Dose (US$/JPY), June’2020
Figure 10-27: Japan – Tecentriq Annual Sales Value (US$/JPY Million), 2017 - 2019
Figure 10-28: Japan – Tecentriq Quarterly Sales Value (US$/JPY Million), 2019
Figure 10-29: Japan – Tecentriq Quarterly Sales Value (US$/JPY Million), 2019
Figure 10-30: Opdivo - FDA & Japan Approval Year
Figure 10-31: Opdivo - Patent Expiration Year by Region
Figure 10-32: Opdivo - Price for 4ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$/JPY), June’2020
Figure 10-33: Opdivo - Price for 10 ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$/JPY), June’2020
Figure 10-34: Opdivo - Price for 20 ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$/JPY), June’2020
Figure 10-35: Opdivo Monotherapy Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$/JPY), June’2020
Figure 10-36: Opdivo Combination – Dose for Management of Melanoma & Renal Cell Carcinoma (mg/3 Weeks)), June’2020
Figure 10-37: Revlimid - FDA & Japan Approval Year
Figure 10-38: Revlimid – FDA Approval Year by Indication
Figure 10-39: Revlimid – FDA Approval & Patent Expiration Year
Figure 10-40: Revlimid – Price for 28 capsules & 100 Capsules of 2.5mg, 5mg & 10mg Capsules (US$/JPY), June’2020
Figure 10-41: Revlimid – Price for 21 capsules & 100 Capsules of 15mg, 20mg & 25mg Capsules (US$/JPY), June’2020
Figure 10-42: Revlimid – Recommended Daily Dose by Indications (mg)
Figure 10-43: Keytruda - FDA & Japan Approval Year
Figure 10-44: Keytruda – Patent Expiration Year by Region
Figure 10-45: Keytruda – Price for 4ml & 8ml Supply & Price per ml of Intravenous Injection (US$/JPY), June’2020
Figure 10-46: Keytruda – Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks), June’2020
Figure 10-47: Keytruda – Cost of Single and Full Treatment using Powder of Injection (US$/JPY), June’2020
Figure 10-48: Keytruda - Cost of Single and Full Treatment using Solution of Injection (US$/JPY), June’2020
Figure 10-49: Ibrutinib – FDA Approval Year by Indication
Figure 10-50: Ibrutinib – FDA Approval Year by Dosage Form
Figure 10-51: Imbruvica - FDA & Japan Approval Year
Figure 10-52: Imbruvica – Price for 90 & 120 Capsule Supplies of 140mg (US$/JPY), June’2020
Figure 10-53: Imbruvica Capsule – Price for 28 Capsule & Price per Unit Capsule of 70mg (US$/JPY), June’2020
Figure 10-54: Imbruvica Tablet – Price for 28 Tablets & Price per Unit Tablet of Various Doses (US$/JPY), June’2020
Figure 10-55: Imbruvica – Recommended Daily Dose by Indication (mg), May’2020
Figure 11-1: Avastin’s Biosimilar - FDA Approval Year
Figure 11-2: Mvasi - Price for 4ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 11-3: Mvasi - Price for 16 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 11-4: Zirabev - Price for 4ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 11-5: Zirabev - Price for 16 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 11-6: Japan - Avastin’s Biosimilar PMDA Approval Year
Figure 11-7: Herceptin’s Biosimilar - FDA Approval Year
Figure 11-8: Japan - Herceptin’s Biosimilar PMDA Approval Year
Figure 11-9: Kanjati: Price for 150 mg and 420 mg Supply of Intravenous Powder for Injection (JPY/US$), April’2020
Figure 11-10: Trazimera: Price for a supply of 150 mg & 420mg Intravenous Powder of (JPY/US$), April’2020
Figure 11-11: Rituxan Biosimilar - FDA Approval Year
Figure 11-12: Japan - Rituxan Biosimilar PMDA Approval Year
Figure 11-13: Ruxience - Price for a supply of 10 ml & Price per ml of Intravenous Solution (JPY/US$), April’2020
Figure 11-14: Ruxience - Price for a supply of 10 ml & Price per ml of Intravenous Solution (JPY/US$), April’2020
Figure 12-1: Japan Cancer Drug Market Drivers
Figure 12-2: Challenges for Japan Cancer Drugs Market
Figure 1-1: Japan – Per Capita Healthcare Expenditure (US$/JPY), 2017 & 2018
Figure 1-2: Japan – Heath care Expenditure (US$/JPY Billion), 2017 & 2018
Figure 1-3: Japan – Per Capita Heath care Expenditure by Age (US$/JPY), 2018
Figure 1-4: Global - Pharmaceutical Market Size by Leading Countries (US$ Billion), 2018
Figure 1-5: Global - Pharmaceutical Market Size by Leading Countries (US$ Billion), 2018
Figure 1-6: Estimated Cancer Cases – Global v/s Japan (Million), 2020
Figure 1-7: Japan – Cancer Drug Market Size (US$ Billion), 2018 - 2025
Figure 1-8: Cancer Drug Market Size – Japan v/s Global (US$ Billion), 2019
Figure 1-9: Cancer Drug Market Size – Japan v/s Global (US$ Billion), 2019
Figure 1-10: Japan – Volume Share of Generics (%), 2011 , 2015, 2017 & 2020
Figure 2-1: Japan – Newly Diagnosed Cancer Cases, 2018, 2020 & 2025
Figure 2-2: Japan – Cancer Deaths Statistics, 2018, 2020 & 2025
Figure 2-3: Age Standardized Cancer Incidence Rate – Japan v/s Global Average (Per 100,000), 2018
Figure 2-4: Age Standardized Cancer Mortality Rate – Japan v/s Global Average (Per 100,000), 2018
Figure 2-5: Japan – Newly Diagnosed Cancer Cases by Type, 2018
Figure 2-6: Japan – Newly Diagnosed Cancer Cases by Type (%), 2018
Figure 2-7: Japan – Cancer Related Deaths by Type, 2018
Figure 2-8: Japan – Newly Diagnosed Colorectum Cancer Cases, 2018, 2020 & 2025
Figure 2-9: Japan – Newly Diagnosed Colorectum Cancer Cases by Type, 2018
Figure 2-10: Japan –Colorectum Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-11: Japan – Age Standardized Colorectum Cancer Incidence & Mortality Rate (Per 100,000), 2018
Figure 2-12: Japan – Newly Diagnosed Lung Cancer Cases, 2018, 2020 & 2025
Figure 2-13: Japan –Lung Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-14: Japan – Age Standardized Lung Cancer Incidence & Mortality Rate (Per 100,000), 2018
Figure 2-15: Japan – Newly Diagnosed Stomach Cancer Cases, 2018, 2020 & 2025
Figure 2-16: Japan – Stomach Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-17: Japan – Age Standardized Stomach Cancer Incidence & Mortality Rate (Per 100,000), 2018
Figure 2-18: Japan – Newly Diagnosed Prostate Cancer Cases, 2018, 2020 & 2025
Figure 2-19: Japan – Prostate Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-20: Japan – Age Standardized Prostate Cancer Incidence & Mortality Rate (Per 100,000), 2018
Figure 2-21: Japan – Newly Diagnosed Breast Cancer Cases, 2018, 2020 & 2025
Figure 2-22: Japan – Breast Cancer Related Deaths, 2018, 2020 & 2025
Figure 2-23: Japan – Age Standardized Breast Cancer Incidence & Mortality Rate (Per 100,000), 2018
Figure 2-24: Japan – Newly Diagnosed Cancer Cases by Gender, 2018
Figure 2-25: Japan – Cancer Deaths by Gender, 2018
Figure 2-26: Japan – Age Standardized Cancer Incidence Rate by Gender (Per 100,000), 2018
Figure 2-27: Japan – Age Standardized Cancer Mortality Rate by Gender (Per 100,000), 2018
Figure 2-28: Japan – Estimated Number of Newly Diagnosed Cancer Cases in Males, 2020 & 2025
Figure 2-29: Japan – Estimated Number of Newly Diagnosed Cancer Cases in Females, 2020 & 2025
Figure 2-30: Japan – Male Cancer Cases by Type, 2018
Figure 2-31: Japan – Male Cancer Cases by Type, 2018
Figure 2-32: Japan – Male Cancer Cases by Type, 2018
Figure 2-33: Japan – Female Cancer Cases by Type, 2018
Figure 2-34: Japan – Female Cancer Cases by Type (%), 2018
Figure 2-35: Japan – Female Cancer Cases by Type, 2018
Figure 2-36: Japan – Newly Diagnosed Cancer Cases by Age, 2018
Figure 2-37: Japan – Newly Diagnosed Cancer Cases by Age (%), 2018
Figure 2-38: Japan – Newly Diagnosed Cancer Cases by Age, 2018
Figure 2-39: Japan – Newly Diagnosed Cancer Cases by Age (%), 2018
Figure 3-1: Japan – PMDA Review Process for Drugs & Medical Devices
Figure 3-2: Japan - PMDA Regulatory System for Practical Application of Cellular & Tissue Based Product
Figure 3-3: Japan - Organisation of PMDA
Figure 3-4: Japan – New Drug Marketing Approval Process
Figure 4-1: Outline of Pricing New Pharmaceuticals
Figure 4-2: Japan - Premium Applied During Price Fixation of New Pharmaceuticals
Figure 4-3: Japan - Components of Cost Calculation Method
Figure 4-4: Japan - Price of New Generic & Oral Generic with more than 10 Brands v/s Original Product (%), April’2020
Figure 4-5: Japan – Price of Biotechnological & Chemically derived Biosimilars v/s Original Products
Figure 4-6: Japan: Price Reduction of Branded Drugs by Generic Replacement Rate (%)
Figure 5-1: Japan – Number of Clinical Trial related to Cancer v/s Total, April’2020
Figure 5-2: Japan – Number of Clinical Trial related to Cancer v/s Total (%), April’2020
Figure 5-3: Japan – Number of Clinical Trial by Phase, April’2020
Figure 5-4: Japan – Number of Clinical Trials by Phase (%), April’2020
Figure 5-5: Japan – Number of Drug In Clinical Trials by Phase, 2020 till 2025
Figure 5-6: Japan – Number of Drug In Clinical Trials by Phase, 2020 till 2025
Figure 5-7: Japan – Number of Clinical Trial by Status, April’2020
Figure 5-8: Japan – Number of Breast Cancer Clinical Trial by Phase, April’2020
Figure 5-9: Japan – Number of Breast Cancer Clinical Trial by Phase (%), April’2020
Figure 5-10: Japan – Number of Breast Cancer Clinical Trial by Status, April’2020
Figure 5-11: Japan – Number of Colorectum Cancer Clinical Trial by Phase, April’2020
Figure 5-12: Japan – Number of Colorectum Cancer Clinical Trial by Phase (%), April’2020
Figure 5-13: Japan – Number of Colorectum Cancer Clinical Trial by Status, April’2020
Figure 5-14: Japan – Number of Prostate Cancer Clinical Trial by Phase, April’2020
Figure 5-15: Japan – Number of Colorectum Cancer Clinical Trial by Phase (%), April’2020
Figure 5-16: Japan – Number of Prostate Cancer Clinical Trial by Status, April’2020
Figure 5-17: Japan – Number of Lung Cancer Clinical Trial by Phase, April’2020
Figure 5-18: Japan – Number of Lung Cancer Clinical Trial by Phase (%), April’2020
Figure 5-19: Japan – Number of Lung Cancer Clinical Trial by Status, April’2020
Figure 5-20: Japan – Number of Stomach Cancer Clinical Trial by Phase, April’2020
Figure 5-21: Japan – Number of Lung Cancer Clinical Trial by Phase (%), April’2020
Figure 5-22: Japan – Number of Lung Cancer Clinical Trial by Status, April’2020
Figure 6-1: Breast Cancer Drug Market Size – Global v/s Japan (US$ Billion), 2019
Figure 6-2: Breast Cancer Drug Market Size – Global v/s Japan (%), 2019
Figure 6-3: Herceptin – Approval Year by Cancer Type
Figure 6-4: Herceptin – FDA approval & PMDA Approval Year
Figure 6-5: Herceptin – Price for a Supply of 10 and Price for Single 150mg Powder for Injection (US$/JPY), June’2020
Figure 6-6: Herceptin – Initial & Maintenance Dose for Breast Cancer Treatment (mg/kg), June’2020
Figure 6-7: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Breast Cancer (US$/JPY), June’2020
Figure 6-8: Herceptin – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), January’2020
Figure 6-9: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$/JPY), January’2020
Figure 6-10: Japan – Herceptin Annual Sales Value (US$/JPY Million), 2017 - 2019
Figure 6-11: Japan – Herceptin Quarterly Sales Value (US$/JPY Million), 2019
Figure 6-12: Japan – Herceptin Quarterly Sales Value (US$/JPY Million), 2019
Figure 6-13: Kadcyla – FDA Approval Year for Late Stage & Early Stage HER2+ Breast Cancer
Figure 6-14; Kadcyla – Price for Single Unit of 100mg & 150mg Intravenous Powder for Injection (US$), June’2020
Figure 6-15: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks), June’2020
Figure 6-16: Kadcyla – Average Cost of Single Treatment Cycle & Full Treatment of Early Stage HER2 Breast Cancer (US$/JPY), June’2020
Figure 6-17: Kadcyla – Recommended Dose After 1st & 2nd Dose Reduction (mg/m2), June’2020
Figure 6-18: Perjeta – FDA & PMDA Approval Year
Figure 6-19: Perjeta – Patent Expiration Year by Region
Figure 6-20: Perjeta – Price for a Supply of 10 ml and Price per ml of Intravenous Solution (US$/JPY), June’2020
Figure 6-21: Perjeta – Initial & Maintenance Dose for Breast Cancer Treatment (mg/ 3 weeks), June’2020
Figure 6-22: Perjeta – Minimum & Maximum Treatment Cost for Breast Cancer (US$/JPY), June’2020
Figure 6-23: Perjeta – Minimum & Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$/JPY), January’2020
Figure 6-24: Japan – Perjeta Annual Sales Value (US$/JPY Million), 2017 - 2019
Figure 6-25: Japan – Perjeta Quarterly Sales Value (US$/JPY Million), 2019
Figure 6-26: Japan – Perjeta Quarterly Sales Value (US$/JPY Million), 2019
Figure 6-27: Enhertu – FDA & PMDA Approval Year
Figure 6-28: Enhertu – Disease Control, Tumor Shrinkage & Disease Elimination Rate (%)
Figure 6-29: Enhertu – Average Cost of Single Treatment Cycle & Annual Treatment Cost of Breast Cancer (US$/JPY), June’2020
Figure 6-30: Enhertu – Recommended Dose & Dose after Reduction (mg/Kg), June’2020
Figure 6-31: Tykerb – FDA & Japan Approval Year
Figure 6-32: Tykerb – Patent Issue & Expiration Year
Figure 6-33: Tykerb – Price for 150 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 6-34: Tykerb – for HER2+ & HER2+ Metastatic Breast Cancer (mg per day), April’2020
Figure 6-35: Tykerb – Treatment & Rest Phase in Single Treatment Cycle (Days)
Figure 6-36: Letrozole – FDA & PMDA Approval Year
Figure 6-37: Letrozole – Price for a Supply of 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-38: Letrozole – Price for a Supply of 50 Tablets & Price per Unit Tablet (US$), June’2020
Figure 6-39: Letrozole – Price for a Supply of 90 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-40: Letrozole – Price for a Supply of 1000 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-41: Femara – Price for a Supply of 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-42: Letrozole – Daily, Monthly & Annual Treatment Cost using Branded & Generic Letrozole (US$), June’2020
Figure 6-43: Anastarzole - FDA & Generic Approval Year
Figure 6-44: Anastrazole - Price for Various Supplies of 1mg Tablet (US$/JPY), June’2020
Figure 6-45: Arimidex – Price for 30 Tablet Supply & Price Per Unit Tablet (US$/JPY), June’2020
Figure 6-46: Anastrazole – Daily, Monthly & Annual Treatment Cost for Breast Cancer (US$), 2020’January
Figure 6-47: Armidex – Daily, Monthly & Annual Treatment Cost for Breast Cancer (US$), 2020’January
Figure 6-48: Megastrol - FDA & Generic Approval Year
Figure 6-49: Megastrol – Price for Various Supplies of 40mg/ml Oral Suspension (US$/JPY), June’2020
Figure 6-50: Megastrol - Price for Supply of 150 ml & Price per ml of 625mg/5ml Oral Suspension (US$/JPY), June’2020
Figure 6-51: Megace ES - Price for Supply of 150 ml & Price per ml of 625mg/5ml Oral Suspension (US$/JPY), June’2020
Figure 6-52: Megastrol - Price for Supply of 100 Tablets & Price per Unit of 20mg Tablet (US$/JPY), June’2020
Figure 6-53: Megastrol - Price for Supply of 100, 250 & 500 Tablets of 40mg (US$/JPY), June’2020
Figure 6-54: Megestrol - Average Cost of Daily, Monthly & Annual Treatment using 40mg/ml Oral Suspension (US$), June’2020
Figure 6-55: Megestrol - Average Cost of Daily, Monthly & Annual Treatment using 40mg Oral Tablet (US$), June’2020
Figure 6-56: Fulvestrant - FDA & PMDA Approval Year
Figure 6-57: Fulvestrant – Average Price for a Supply of 10ml, 5ml & Price per ml of Intramuscular Solution (US$/JPY), June’2020
Figure 6-58: Faslodex – Average Price for a Supply of 10ml, 5ml & Price per ml of Intramuscular Solution (US$/JPY), June’2020
Figure 6-59: Fulvestrant – Number of Dose Administration in Initial & Subsequent Months, January’2020
Figure 6-60: Fulvestrant – Treatment Cost of Initial & Subsequent Months (US$), January’2020
Figure 6-61: Fulvestrant – Treatment Cost of Initial & Subsequent Year (US$), January’2020
Figure 6-62: Faslodex – Treatment Cost of Initial & Subsequent Months (US$), January’2020
Figure 6-63: Faslodex – Treatment Cost of Initial & Subsequent Year (US$), January’2020
Figure 6-64: Toremifene - FDA & First Generic Approval Year
Figure 6-65: Toremifene – Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-66: Fareston – Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-67: Toremifene - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020’January
Figure 6-68: Fareston - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020’January
Figure 6-69: Exemestane - FDA & First Generic Approval Year
Figure 6-70: Exemestane – Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-71: Aromasin – Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 6-72: Exemestane - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020’January
Figure 6-73: Aromasin - Average Cost of Daily, Monthly & Annual Treatment of Breast Cancer (US$), 2020’January
Figure 6-74: Verzenio – FDA & PMDA Approval Year
Figure 6-75: Verzenio – Patent Issue & Expiration Year
Figure 6-76: Verzenio - Price for a Supply of 14 Tablets & Price per unit of Tablet (US$/JPY), June’2020
Figure 6-77: Verzenio - Recommanded Dose Modification for Adverse Effects in Monotherapy (mg)
Figure 6-78: Verzenio - Recommanded Dose Modification for Adverse Effects in Combinational Therapy (mg)
Figure 6-79: Ibrance – FDA & PMDA Approval Year
Figure 6-80: Ibrance - Year of Assigning & Expiration of Different Patents
Figure 6-81: Ibrance – Price for a Supply of 21 Capsules & Per Unit Cost of Ibrance Capsules (US$/JPY), June’2020
Figure 6-82: Ibrance – Treatment Cycle of Ibrance using 1 Capsule/Day (Days)
Figure 6-83: Ibrance – Recommanded Dose Modification for Adverse effects (mg)
Figure 7-1: Xtandi – FDA & Japan Approval Year
Figure 7-2: Xtandi – Patent Issue & expiration Year
Figure 7-3: Xtandi – Price for 120 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 7-4: Xtandi – Recommended & Reduced Dose for Prostate Cancer Treatment (mg per day), April’2020
Figure 7-5: Xtandi – Cost of Single Capsule & Daily Treatment Cost (JPY/US$), April’2020
Figure 7-6: Erleada – FDA & Japan Approval Year
Figure 7-7: Erleada – Aragon related Patent Issue & expiration Year
Figure 7-8: Erleada – University of California related Patent Issue & expiration Year
Figure 7-9: Erleada – Price for 120 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 7-10: Erleada – Recommended & Reduced Dose for Prostate Cancer Treatment (mg per day), April’2020
Figure 7-11: Nubeqa – FDA & Japan Approval Year
Figure 7-12: Nubeqa – Aragon related Patent Issue & Expiration Year
Figure 7-13: Nubeqa – Price for 120 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 7-14: Nubeqa – Price of Single Tablet & Daily Treatment Cost (JPY/US$), April’2020
Figure 7-15: Xofigo – FDA & Japan Approval Year
Figure 7-16: Xofigo – Patent Issue & expiration Year
Figure 7-17: Xofigo – Duration of One Treatment Cycle & Full Treatment Duration for Prostate Cancer (Weeks), April’2020
Figure 7-18: Abiraterone - FDA & PMDA Approval Year
Figure 7-19: Aberaterone – Price of 30 Tablets & Price per unit of 250mg Tablet (US$/JPY), June’2020
Figure 7-20: Aberaterone – Price of 120 Tablets & Price per Unit of 250mg Tablet (US$/JPY), June’2020
Figure 7-21: Zytiga – Price of 120 Tablets & Price per unit of 250mg Tablet (US$/JPY), June’2020
Figure 7-22: Zytiga – Price of 60 Tablets & Price per Unit of 500mg Tablet (US$/JPY), June’2020
Figure 7-23: Abiraterone – Treatment Cost Comparision of Metastatic High-risk CSPC Using Branded & Generic Tablet (US$), January’2020
Figure 7-24: Abiraterone – Treatment Cost Comparision of Metastatic CSPC Using Branded & Generic Tablet (US$), January’2020
Figure 7-25: Bicalutamide - FDA & First Generic Approval Year
Figure 7-26: Bicalutamide - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 7-27: Casodex - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 7-28: Bicalutamide – Price of 100 Tablets & Price per Unit of 50mg Tablet (US$/JPY), June’2020
Figure 7-29: Bicalutamide – Price of 500 Tablets & Price per Unit of 50mg Tablet (US$/JPY), June’2020
Figure 7-30: Bicalutamide – Treatment Cost Comparision of Prostate Cancer Using Branded & Generic Tablet (US$), January’2020
Figure 7-31: Nilutamide - FDA & First Generic Approval Year
Figure 7-32: Nilutamide - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 7-33: Nilandron - Price for 30 Tablets & Price per Unit Tablet (US$/JPY), June’2020
Figure 7-34: Nilutamide – Initial & Maintenance Dose for Prostate Cancer Treatment (mg/day)
Figure 7-35: Nilutamide – Comparision of Initial Month Treatment Cost of Prostate Cancer Using Branded & Generic Tablet (US$), June’2020
Figure 7-36: Nilutamide – Comparision of Maintenence Month Treatment Cost of Prostate Cancer Using Branded & Generic Tablet (US$), June’2020
Figure 7-37: Flutamide - FDA & First Generic Approval Year
Figure 7-38: Flutamide - Price for 180 Capsules & Price per Unit Capsule (US$/JPY), June’2020
Figure 7-39: Eulexin - Price for 180 Capsules & Price per Unit Capsule (US$/JPY), June’2020
Figure 7-40: Flutamide – Comparision of Daily, Monthly & Annual Treatment of Prostate Cancer Using Branded & Generic Capsule (US$), January’2020
Figure 8-1: Alimta – FDA & Japan Approval Year
Figure 8-2: Alimta – Patent Issue & expiration Year
Figure 8-3: Alimta – Price for 120 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 8-4: Alimta – Number of Treatment Cycle Required in Combination with Pembtrolizumab & Cisplatin , April’2020
Figure 8-5: Alecensa – FDA & Japan Approval Year
Figure 8-6: Alecensa - Patent Issue & expiration Year
Figure 8-7: Alecensa – Price for 240 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 8-8: Alecensa - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 8-9: Gilotrif – FDA & Japan Approval Year
Figure 8-10: Gilotrif - Patent Issue & expiration Year
Figure 8-11: Gilotrif – Price for 30 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 8-12: Gilotrif - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 8-13: Iressa – FDA & Japan Approval Year
Figure 8-14: Iressa – Price for 30 Tablet Supply & Price per Unit of Oral Tablet (JPY/US$), April’2020
Figure 8-15: Lorbrena – FDA Approval, Japan Approval & Patent expiration Years
Figure 8-16: Lorbrena - Price for 30 Tablet Supply & Price per unit of 25mg Oral Tablet (JPY/US$), April’2020
Figure 8-17: Lorbrena - Price for 30 Tablet Supply & Price per unit of 100 mg Oral Tablet (JPY/US$), April’2020
Figure 8-18: Lorbrena - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 8-19: Portrazza - FDA & Japan Approval Year
Figure 8-20: Portrazza - Price for 50 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 8-21: Portrazza – Cost of Single Treatment Cycle & Annual Treatment Cost of NSCLC (JPY/US$), April’2020
Figure 8-22: Rozlytrek - FDA Approval, Japan Approval & Patent Expiration Year
Figure 8-23: Rozyltrek - Price for 30 Capsules Supply & Price per Unit of 100 mg Oral Tablet (JPY/US$), April’2020
Figure 8-24: Rozyltrek - Price for 90 Capsules Supply & Price per unit of 200 mg Oral Tablet (JPY/US$), April’2020
Figure 8-25: Rozyltrek – Pediatric Dose by Surface Area (mg), April’2020
Figure 8-26: Tagrisso - FDA & Japan Approval Year
Figure 8-27: Tagrisso - Patent Issue & Expiration Year
Figure 8-28: Tagrisso - Price for 30 Tablet Supply & Price per Unit of 200 mg Oral Tablet (JPY/US$), April’2020
Figure 8-29: Tagrisso - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 8-30: Vizimpro - FDA & Japan Approval Year
Figure 8-31: Vizimpro - Patent Issue & Expiration Year
Figure 8-32: Vizimpro - Price for 30 Tablet Supply & Price per Unit of 200 mg Oral Tablet (JPY/US$), April’2020
Figure 8-33: Vizimpro - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 8-34: Xalkori - FDA & Japan Approval Year
Figure 8-35: Xalkori - Patent Issue & Expiration Year
Figure 8-36: Xalkori - Price for 60 Capsule Supply & Price per Unit of Oral Capsule (JPY/US$), April’2020
Figure 8-37: Zykadia - FDA & Japan Approval Year
Figure 8-38: Zykadia - Patent Expiration Year by Assignee
Figure 8-39: Zykadia - Price for 84 Capsules Supply & Price per Unit of Oral Capsule (JPY/US$), April’2020
Figure 8-40: Zykadia - Recommended & Reduced Dose for NSCLC Treatment (mg per day), April’2020
Figure 8-41: Vinorelbine - FDA & First Generic Approval Year
Figure 8-42: Vinorelbine - Price for 5ml Supply & Price per ml of Intravenous Solution (US$/JPY), June’2020
Figure 8-43: Vinorelbine - Price for 5ml Supply & Price per ml of Intravenous Solution (US$/JPY), June’2020
Figure 8-44: Vinorelbine Monotherapy – Comparision of Treatment Cost of NSCLC Using Branded & Generic Intravenous Solution (US$), January’2020
Figure 8-45: Vinorelbine – Combinational Dose with 100mg/m2 and 120 mg/m2 Cisplatin (mg/m2), January’2020
Figure 9-1: Lonsurf – FDA Approval, Japan Approval & Patent Expiration Year
Figure 9-2: Lonsurf - Price for Various Supplies of 6.14 mg-15 mg Tablet (JPY/US$), April’2020
Figure 9-3: Lonsurf - Price for Various Supplies of 8.19mg-20mg Tablet (JPY/US$), April’2020
Figure 9-4: Lonsurf - Recommended Dose by Surface Area (mg per day)
Figure 9-5: Vectibix – FDA & Japan Approval Year
Figure 9-6: Vectibix - Price for 5 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 9-7: Vectibix - Price for 20 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 9-8: Zaltrap - FDA & Japan Approval Year
Figure 9-9: Zaltrap - Price for 4 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 9-10: Zaltrap - Price for 8ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 9-11: Irinotecan - FDA & First Generic Approval Year
Figure 9-12: Irinotecan – Price for Various Supplies of Intravenous Solution (US$/JPY), June’2020
Figure 9-13: Camptosar – Price for Various Supplies of Intravenous Solution (US$/JPY), June’2020
Figure 9-14: Irinotecan – Minimum & Maximum Duration of Treatment Cycle (Weeks), January ’2020
Figure 9-15: Oxaliplatin - FDA & PMDA Approval Year
Figure 9-16: Oxaliplatin – Price of 50 mg & 100 mg Intravenous Powder for Injection (US$/JPY), June’2020
Figure 9-17: Oxaliplatin – Price of 10ml & 1ml Intravenous Solution for Injection (US$/JPY), June’2020
Figure 9-18: Eloxatin – Price of 10ml & 1ml Intravenous Solution for Injection (US$/JPY), June’2020
Figure 9-19: Eloxatin – Price of 20ml & 1ml Intravenous Solution for Injection (US$/JPY), June’2020
Figure 9-20: Oxaplatin – Duration of Single Treatment Cycle & Full Treatment of Stage III Colon Cancer (Weeks), 2020’January
Figure 10-1: Avastin – FDA & PMDA Approval Year
Figure 10-2: Avastin – Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US$/JPY), June’2020
Figure 10-3: Avastin – Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US$/JPY), June’2020
Figure 10-4: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$/JPY), June’2020
Figure 10-5: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$/JPY), June’2020
Figure 10-6: Avastin – Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks), June’2020
Figure 10-7: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$/JPY), June’2020
Figure 10-8: Japan – Avastin Annual Sales Value (US$/JPY Million), 2017 - 2019
Figure 10-9: Japan – Avastin Quarterly Sales Value (US$/JPY Million), 2019
Figure 10-10: Japan – Avastin Quarterly Sales Value (US$/JPY Million), 2019
Figure 10-11: Gazyva – FDA Approval Year by Indication
Figure 10-12: Rituxan - FDA & Japan Approval Year
Figure 10-13: Rituxan – Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$/JPY), June’2020
Figure 10-14: Rituxan – Price for a Supply of 50 ml & Price per ml of Solution for Injection (US$/JPY), June’2020
Figure 10-15: Rituxan – Price for a Supply of 100 ml & Price per ml of Solution for Injection (US$/JPY), June’2020
Figure 10-16: Rituxan – Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$/JPY), June’2020
Figure 10-17: Rituxan – Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June’2020
Figure 10-18: Japan – Rituxan Annual Sales Value (US$/JPY Million), 2017 - 2019
Figure 10-19: Japan – Rituxan Quarterly Sales Value (US$/JPY Million), 2019
Figure 10-20: Japan – Rituxan Quarterly Sales Value (US$/JPY Million), 2019
Figure 10-21: Tecentriq - FDA & Japan Approval Year
Figure 10-22: Tecentriq - Price for 14ml Supply & Price per ml of 840mg/14ml Intravenous Injection (US$/JPY), June’2020
Figure 10-23: Tecentriq - Price for 20ml Supply & Price per ml of 1200mg/20ml Intravenous Injection (US$/JPY), June’2020
Figure 10-24: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 840mg/m2 Week Dose (US$/JPY), June’2020
Figure 10-25: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1200mg/3 Week Dose (US$/JPY), June’2020
Figure 10-26: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1680mg/4 Week Dose (US$/JPY), June’2020
Figure 10-27: Japan – Tecentriq Annual Sales Value (US$/JPY Million), 2017 - 2019
Figure 10-28: Japan – Tecentriq Quarterly Sales Value (US$/JPY Million), 2019
Figure 10-29: Japan – Tecentriq Quarterly Sales Value (US$/JPY Million), 2019
Figure 10-30: Opdivo - FDA & Japan Approval Year
Figure 10-31: Opdivo - Patent Expiration Year by Region
Figure 10-32: Opdivo - Price for 4ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$/JPY), June’2020
Figure 10-33: Opdivo - Price for 10 ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$/JPY), June’2020
Figure 10-34: Opdivo - Price for 20 ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$/JPY), June’2020
Figure 10-35: Opdivo Monotherapy Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$/JPY), June’2020
Figure 10-36: Opdivo Combination – Dose for Management of Melanoma & Renal Cell Carcinoma (mg/3 Weeks)), June’2020
Figure 10-37: Revlimid - FDA & Japan Approval Year
Figure 10-38: Revlimid – FDA Approval Year by Indication
Figure 10-39: Revlimid – FDA Approval & Patent Expiration Year
Figure 10-40: Revlimid – Price for 28 capsules & 100 Capsules of 2.5mg, 5mg & 10mg Capsules (US$/JPY), June’2020
Figure 10-41: Revlimid – Price for 21 capsules & 100 Capsules of 15mg, 20mg & 25mg Capsules (US$/JPY), June’2020
Figure 10-42: Revlimid – Recommended Daily Dose by Indications (mg)
Figure 10-43: Keytruda - FDA & Japan Approval Year
Figure 10-44: Keytruda – Patent Expiration Year by Region
Figure 10-45: Keytruda – Price for 4ml & 8ml Supply & Price per ml of Intravenous Injection (US$/JPY), June’2020
Figure 10-46: Keytruda – Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks), June’2020
Figure 10-47: Keytruda – Cost of Single and Full Treatment using Powder of Injection (US$/JPY), June’2020
Figure 10-48: Keytruda - Cost of Single and Full Treatment using Solution of Injection (US$/JPY), June’2020
Figure 10-49: Ibrutinib – FDA Approval Year by Indication
Figure 10-50: Ibrutinib – FDA Approval Year by Dosage Form
Figure 10-51: Imbruvica - FDA & Japan Approval Year
Figure 10-52: Imbruvica – Price for 90 & 120 Capsule Supplies of 140mg (US$/JPY), June’2020
Figure 10-53: Imbruvica Capsule – Price for 28 Capsule & Price per Unit Capsule of 70mg (US$/JPY), June’2020
Figure 10-54: Imbruvica Tablet – Price for 28 Tablets & Price per Unit Tablet of Various Doses (US$/JPY), June’2020
Figure 10-55: Imbruvica – Recommended Daily Dose by Indication (mg), May’2020
Figure 11-1: Avastin’s Biosimilar - FDA Approval Year
Figure 11-2: Mvasi - Price for 4ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 11-3: Mvasi - Price for 16 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 11-4: Zirabev - Price for 4ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 11-5: Zirabev - Price for 16 ml Supply & Price per Unit of Intravenous Solution (JPY/US$), April’2020
Figure 11-6: Japan - Avastin’s Biosimilar PMDA Approval Year
Figure 11-7: Herceptin’s Biosimilar - FDA Approval Year
Figure 11-8: Japan - Herceptin’s Biosimilar PMDA Approval Year
Figure 11-9: Kanjati: Price for 150 mg and 420 mg Supply of Intravenous Powder for Injection (JPY/US$), April’2020
Figure 11-10: Trazimera: Price for a supply of 150 mg & 420mg Intravenous Powder of (JPY/US$), April’2020
Figure 11-11: Rituxan Biosimilar - FDA Approval Year
Figure 11-12: Japan - Rituxan Biosimilar PMDA Approval Year
Figure 11-13: Ruxience - Price for a supply of 10 ml & Price per ml of Intravenous Solution (JPY/US$), April’2020
Figure 11-14: Ruxience - Price for a supply of 10 ml & Price per ml of Intravenous Solution (JPY/US$), April’2020
Figure 12-1: Japan Cancer Drug Market Drivers
Figure 12-2: Challenges for Japan Cancer Drugs Market
